Tissue Regenix Group PLC Notice of Results (7985V)
April 19 2021 - 1:00AM
UK Regulatory
TIDMTRX
RNS Number : 7985V
Tissue Regenix Group PLC
19 April 2021
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Notice of Results
Investor Presentation
Tissue Regenix (AIM: TRX), the regenerative medical devices
company, will announce its final results for the year ended 31
December 2020 on Wednesday 28 April 2021.
Investor Briefing
Daniel Lee, Chief Executive Officer, and David Cocke, Chief
Financial Officer, will be hosting a live online presentation
relating to the final results via the Investor Meet Company
platform at 4.30pm on Wednesday 28 April 2021. The presentation is
open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and
register for the presentation here:
https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
Investors who already follow Tissue Regenix on the Investor Meet
Company platform will automatically be invited.
Questions can be submitted pre-event via your IMC dashboard or
in real time during the presentation, via the "Ask a Question"
function. Whilst the Company may not be in a position to answer
every question it receives, it will address the most prominent
within the confines of information already disclosed to the market
through regulatory notifications. A recording of the presentation,
a PDF of the slides used, and responses to the Q&A session will
be available on the Investor Meet Company platform afterwards.
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44(0)20 7710 7600
and Broker)
Ben Maddison / Alex Price
Walbrook PR Ltd Tel: +44 (0)20 7933 8780
Alice Woodings / Lianne Cawthorne / Paul McManus TissueRegenix@walbrookpr.com
About Tissue Regenix ( www.tissueregenix.com )
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or worn-out body parts. Current
applications address many critical clinical needs such as sports
medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and soft tissue scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, foot & ankle, dental, and sports medicine surgical
procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORDZGMDVVDGMZM
(END) Dow Jones Newswires
April 19, 2021 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2023 to Apr 2024